Form 10-Q · Quarterly report
Teledyne Technologies 10-Q, filed Oct 23, 2026
- Filed
- CIK
- 0001094285
- Accession no.
- 0001094285-26-000059
Summary
Teledyne Technologies reported third-quarter 2026 net sales of $1.68 billion, up 9.4% from a year earlier, with net income attributable to Teledyne of $272.8 million, up 23.6%, and diluted earnings per share of $5.82 versus $4.65. The company said it has not seen a material adverse impact from Middle East conflicts, is working to mitigate tariffs and China's restrictions on rare-earth mineral exports, and that a February 2026 U.S. Supreme Court ruling invalidated IEEPA tariffs, for which it filed refund claims and received substantially all of them by the end of the third quarter.
Key points
- Third-quarter 2026 net sales rose in all four segments, led by Digital Imaging at $903.0 million, up 15.0%.
- Operating income for the quarter rose 22.8% to $347.2 million, with Digital Imaging operating income up 48.1% to $182.7 million.
- Teledyne plans approximately $140 million in 2026 capital expenditures and continues facility consolidation, product rationalization and headcount reductions to cut costs.
- The company said it continues to benefit from increased global defense spending and that further U.S. government shutdowns could delay contract awards, export licenses, shipments and payments.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview Teledyne provides enabling technologies to sense, analyze and distribute information for industrial growth markets that require advanced technology and high reliability. These markets include aerospace and defense, factory automation, air and water quality environmental monitoring, electronics design and development, oceanographic research, deepwater oil and gas exploration and production, medical imaging, and pharmaceutical research. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.